Modulating the AIBP-CAV1-VEGFR3 axis to treat lymphatic disorders
This invention is a method of promoting lymphangiogenesis in order to treat lymphatic disorders, namely lymphedema and Alzheimer’s disease (AD). VEGFC-induced VEGFR3 signaling is the major driver of lymphangiogenesis, however the distinct molecular mechanisms determining how VEGFR3 signaling controls lymphatic endothelial cell (LEC) fate remains...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Jun-dae Kim
Keywords(s):
Category(s): Clinical Area > Metabolic Disease, Inflammation, and Immunology, Clinical Area > Neurology, Clinical Area > Cardiovascular, Research Area > Heart and Vascular, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Biologics
|